BVX - Bovie Medical Corporation

NYSE American - NYSE American Delayed Price. Currency in USD
5.15
0.00 (0.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.15
Open5.15
Bid0.00 x 1000
Ask0.00 x 1000
Day's Range5.04 - 5.18
52 Week Range2.17 - 5.49
Volume76,131
Avg. Volume114,893
Market Cap169.332M
Beta-1.42
PE Ratio (TTM)N/A
EPS (TTM)-0.14
Earnings DateMay 14, 2018 - May 18, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.67
Trade prices are not sourced from all markets
  • MarketWatch8 days ago

    Bovie Medical's stock jumps after deal to sell core business

    Bovie Medical Corp.'s stock (bvx) soared 10% toward a 20-month high in premarket trade Monday, after the medical device company said it reached a deal to sell its "core" business and the Bovie brand for $97 million in cash to Symmetry Surgical Inc. As part of the deal, which is expected to close in the third quarter of 2018, Bovie said it will enter into transition services, patent licensing, disposables supply and generator manufacturing and supply agreements with Symmetry. "This is a milestone moment for the Company, one that creates significant value for our shareholders by significantly enhancing our balance sheet with the addition of more than $70 million in estimated net cash proceeds after taxes and transaction related expenses and allowing us to further focus the organization on our strategic objective of commercializing our J-Plasma/Renuvion technology in the cosmetic surgery market," said Chief Executive Charlie Goodwin.

  • Business Wire8 days ago

    Bovie Medical Corporation Announces Agreement to Sell “Core” Business Segment to Symmetry Surgical, Inc. for Total Cash Consideration of $97 million

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced that the Company has entered into a definitive agreement with Specialty Surgical Instrumentation Inc., a subsidiary of Symmetry Surgical Inc. (“Symmetry”), pursuant to which the Company will divest and sell the Core business segment and the Bovie® brand to Symmetry for gross proceeds of $97 million in cash. The asset purchase agreement was approved by the Company’s Board of Directors and is subject to customary closing conditions – including approval by the Company’s stockholders – and expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

  • Business Wire8 days ago

    Bovie Medical Corporation Announces Preliminary Second Quarter 2018 Revenue Results

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced preliminary revenue results for the second quarter of fiscal year 2018.

  • Business Wire2 months ago

    Bovie Medical Corporation to Participate in the JMP Securities 2018 Life Science Conference

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced that management will participate in the JMP Securities 2018 Life Science Conference at the St. Regis New York in New York, New York. A live audio webcast of the presentation will be provided under the ‘Company Events’ section of the Bovie Medical investor relations website at http://www.boviemedical.com/investor_relations/. Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma® (marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market), a patented plasma-based surgical product for cutting, coagulation and ablation of soft tissue.

  • ACCESSWIRE2 months ago

    Wired News - Microbot Medical Shares Results from the In-Vitro Study of its Self-Cleaning Shunt

    LONDON, UK / ACCESSWIRE / May 23, 2018 / If you want access to our free research report on Microbot Medical Inc. (NASDAQ: MBOT), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=MBOT as the Company's latest news hit the wire. On May 21, 2018, the medical device Company, which is specializing in the design and development of transformational micro-robotic medical technologies, declared the results of its pre-clinical study evaluating the Company's Self-Cleaning Shunt (SCS). Active-Investors.com is currently working on the research report for Bovie Medical Corporation (NYSE AMER: BVX), which also belongs to the Healthcare sector as the Company Microbot Medical.

  • ACCESSWIRE2 months ago

    Blog Exposure - Valeritas Presented Positive Clinical Results from Two New Studies Assessing V-Go Wearable Insulin Delivery Device in Type-2 Diabetes

    LONDON, UK / ACCESSWIRE / May 22, 2018 / If you want access to our free research report on Valeritas Holdings, Inc. (NASDAQ: VLRX), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=VLRX as the Company's latest news hit the wire. On May 18, 2018, the Company reported positive results from two new studies assessing its V-Go Wearable Insulin Delivery device, during poster presentations at the American Association of Clinical Endocrinologists Annual Scientific and Clinical Congress held in Boston, Massachusetts. Active-Investors.com is currently working on the research report for Bovie Medical Corporation (NYSE AMER: BVX), which also belongs to the Healthcare sector as the Company Valeritas Holdings.

  • Benzinga2 months ago

    Benzinga's Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 14) ABIOMED, Inc. (NASDAQ: ABMD ) Bio-Rad Laboratories, Inc. (NYSE: ...

  • Associated Press2 months ago

    Bovie: 1Q Earnings Snapshot

    The Clearwater, Florida-based company said it had a loss of 3 cents per share. The medical device maker posted revenue of $9.9 million in the period. Bovie expects full-year revenue in the range of $41 ...

  • Business Wire2 months ago

    Bovie Medical Corporation Reports First Quarter 2018 Financial Results; Reaffirms Fiscal Year 2018 Financial Outlook

    Bovie Medical Corporation , a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today reported financial results for its first quarter ended March 31, 2018.

  • Business Wire2 months ago

    Bovie Medical Corporation Announces Completion of Enrollment in J-Plasma®/RenuvionTM Dermal Resurfacing Study

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced the completion of enrollment for the U.S. Investigational Device Exemption (IDE) clinical study of its J-Plasma/Renuvion technology for use in dermal skin resurfacing. “We are excited to announce that today we have enrolled the final patient in our dermal skin resurfacing study, which represents another important development in our strategy to build clinical support for our Renuvion technology and expand its clinical indications for use in the cosmetic surgery market,” said Charlie Goodwin, Chief Executive Officer.

  • ACCESSWIRE2 months ago

    Bovie Medical Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 14, 2018 / Bovie Medical Corporation (NYSE American: BVX ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 14, 2018 at 4:30 PM Eastern ...

  • Business Wire2 months ago

    Bovie Medical Corporation Announces Appointment of Diane I. Duncan, M.D., FACS to Medical Advisory Board

    Bovie Medical Corporation (BVX) (the "Company"), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced the appointment of Diane I. Duncan, M.D., FACS to the Company’s Medical Advisory Board. “Dr. Duncan joins our Medical Advisory Board with over 30 years of experience in private practice as a plastic surgeon,” said Charlie Goodwin, Chief Executive Officer.

  • Business Wire3 months ago

    Bovie Medical Corporation to Release First Quarter of Fiscal Year 2018 Financial Results on May 14, 2018

    Bovie Medical , a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, today announced that financial results for the first quarter of fiscal year 2018 will be released after the market closes on Monday, May 14.

  • Business Wire4 months ago

    Bovie Medical Corporation Announces Launch of Renuvion™: A New Brand Dedicated to the Cosmetic Surgery Market

    Bovie Medical Corporation , a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product, today announced the launch of Renuvion™, a new brand that is dedicated to the cosmetic surgery market.

  • Business Wire4 months ago

    Bovie Medical Corporation Announces Appointment of Scott R. Sanders as Director of Clinical Education and Market Development

    Bovie Medical Corporation , a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product, today announced the appointment of Scott R.

  • Associated Press4 months ago

    Bovie reports 4Q loss

    On a per-share basis, the Purchase, New York-based company said it had a loss of 3 cents. The medical device maker posted revenue of $11.3 million in the period. For the year, the company reported that ...

  • Business Wire4 months ago

    Bovie Medical Corporation Reports Fourth Quarter and Full Year 2017 Financial Results; Provides Fiscal Year 2018 Financial Outlook

    Bovie Medical Corporation , a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product, today reported financial results for its fourth quarter and full year ended December 31, 2017.

  • Business Wire4 months ago

    Bovie Medical Corporation Announces Appointment of Craig A. Swandal to Board of Directors

    Bovie Medical Corporation , a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product, today announced the appointment of Craig A.

  • ACCESSWIRE4 months ago

    Bovie Medical Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 12, 2018 / Bovie Medical Corporation (Nyse American: BVX ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 12, 2018 at 4:30 PM ...

  • Business Wire4 months ago

    Bovie Medical Corporation Announces Appointment of Dr. Topaz J. Kirlew as Director of Regulatory Affairs

    Bovie Medical Corporation , a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, today announced the appointment of Dr.

  • Business Wire5 months ago

    Bovie Medical Corporation to Release Fourth Quarter and Fiscal Year 2017 Financial Results on March 12, 2018

    Bovie Medical , a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, today announced that financial results for the fourth quarter and fiscal year of 2017 will be released after the market closes on Monday, March 12.

  • Business Wire6 months ago

    Bovie Medical Corporation Announces Enrollment of First Patient in J-Plasma® Dermal Resurfacing Clinical Study

    Bovie Medical Corporation , a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, today announced that it has enrolled the first patient in a U.S.

  • Business Wire7 months ago

    Bovie Medical Corporation Appoints Charles D. Goodwin Chief Executive Officer; Updates 2017 Outlook

    Bovie Medical Corporation , a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, today announced that Charles D.